$1.56 billion in 2026 is projected to grow to $3.53 billion by 2036, according to the latest forecast for immune digestive support products.
8.5% annual growth is tied to a shift from broad wellness claims toward documented daily-use supplements, with dosage clarity, ingredient evidence and batch consistency becoming more important in supplier selection.
60.2% of U.S. adults used dietary supplements in 2021-2023, while FDA updates to new dietary ingredient notifications in June 2025 and a 75-day filing rule are expected to tighten launch and listing scrutiny.
Capsules, plant-based inputs, immunity-focused products and e-commerce lead 2026 segment demand, with shares of 37.0%, 34.5%, 41.0% and 39.0% respectively.
India is forecast to post the fastest country growth at 7.7% CAGR, ahead of China at 6.4%, as digital commerce and targeted wellness adoption expand.